Icon Plc $ICLR Shares Sold by Fayez Sarofim & Co

Fayez Sarofim & Co lessened its stake in shares of Icon Plc (NASDAQ:ICLR) by 29.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 66,433 shares of the medical research company’s stock after selling 27,920 shares during the quarter. Fayez Sarofim & Co’s holdings in Icon were worth $11,626,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Private Trust Co. NA raised its stake in Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Ameriflex Group Inc. acquired a new position in Icon in the third quarter valued at $33,000. Wilmington Savings Fund Society FSB grew its holdings in shares of Icon by 153.4% during the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after purchasing an additional 201 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Icon during the third quarter worth about $63,000. Finally, Johnson Financial Group Inc. acquired a new stake in shares of Icon during the third quarter worth about $71,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $98.33 on Monday. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The stock has a market capitalization of $7.94 billion, a price-to-earnings ratio of 13.31, a PEG ratio of 2.52 and a beta of 1.36. The company has a 50-day simple moving average of $144.09 and a 200-day simple moving average of $165.40. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ICLR. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Jefferies Financial Group set a $135.00 price target on Icon and gave the stock a “buy” rating in a research note on Monday, February 23rd. Robert W. Baird set a $119.00 price target on Icon in a research report on Friday, February 13th. Truist Financial reiterated a “hold” rating and issued a $222.00 price objective (down from $231.00) on shares of Icon in a research note on Thursday, January 8th. Finally, Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Six equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Icon currently has a consensus rating of “Hold” and an average target price of $146.80.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.